Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788461 | 0.88 | KDM4C (0.41) | KMT2ASMN1; SMN2KDM4CGAADHFR | |
| SCHEMBL6342508 | 0.88 | KDM4C (0.41) | KMT2ASMN1; SMN2KDM4CGAADHFR | |
| SCHEMBL21916301 | 0.85 | DHFR (0.38) | KMT2AKDM4CDHFRPDE4BPTPN1 | |
| SCHEMBL30824895 | 0.84 | SLC6A2 (0.36) | HPGDLMNAKMT2AHTTSMN1; SMN2 | |
| SCHEMBL27390412 | 0.84 | SLC6A2 (0.36) | HPGDLMNAKMT2AHTTSMN1; SMN2 | |
| SCHEMBL16426107 | 0.84 | PTPN1 (0.38) | HPGDLMNAKMT2AHTTSMN1; SMN2 | |
| SCHEMBL11140998 | 0.82 | PDE4B (0.39) | KMT2ADHFRPDE4BPTPN1 | |
| SCHEMBL8954669 | 0.82 | DHFR (0.43) | HPGDLMNAKMT2AHTTSMN1; SMN2 | |
| SCHEMBL1423603 | 0.81 | L3MBTL1 (0.42) | KMT2AKDM4CRAB9ADHFRPDE4B | |
| SCHEMBL2780758 | 0.81 | L3MBTL1 (0.42) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150340627-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20150340627-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2015-11-26 | — | — | US | disclosed |
| WO-2014106524-A2 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2014-07-10 | — | — | WO | disclosed |
| US-8617723-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20110012100-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-1501840-B1 | BRIDGED BI-AROMATIC LIGANDS, COMPLEXES, CATALYSTS, PROCESSES FOR POLYMERIZING AND POLYMERS THEREFROM | SYMYX SOLUTIONS INC (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2254896-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-7659415-B2 | Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom | SYMYX SOLUTIONS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659415-B2 | Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom | SYMYX SOLUTIONS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2009118087-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-5698700-A | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN (US) | 1997-12-16 | — | — | US | disclosed |
| WO-1997027189-A1 | HALOGEN PYRIMIDINES AND ITS USE THEREOF AS PARASITE ABATEMENT MEANS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-31 | — | — | WO | disclosed |
| EP-0749418-A1 | L-N6 -(1-IMINOETHYL)LYSINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996033716-A1 | RARβ SELECTIVE RETINOID COMPOUNDS FOR INHIBITING GENE EXPRESSION PROMOTED BY AP1 PROTEIN AND THEIR USE IN THERAPY | ALLERGAN (US) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996020938-A1 | ACETYLENES DISUBSTITUTED WITH 2-TETRAHYDROPYRANOXYARYL AND ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020937-A1 | ACETYLENES DISUBSTITUTED WITH HYDROXYARYL AND ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5534641-A | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-07-09 | — | — | US | disclosed |
| US-5498795-A | ANTITUMOR AGENTS, SKIN DISORDERS, ATHEROSCLEROSIS, PROSTATE CANCER AND AUTOIMMUNE DISEASES | ALLERGAN, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| WO-1995024382-A1 | L-N6-(1-IMINOETHYL)LYSINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-09-14 | — | — | WO | disclosed |
| US-4943566-A | ANTAGONISTIC TOWARD GLUCOCORTICOIDS AND PROGESTERONE | ROUSSEL UCLAFI | 1990-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150340627-A1 | MATERIALS FOR ELECTRONIC DEVICES | ESR1, EPX, SDHB | HPGD 1225/4885LMNA 3804/4885KMT2A 1847/4885 |
| US-20110012100-A1 | METAL COMPLEXES | AP1M1, AP3M1, SOD1 | HPGD 2964/4885LMNA 3906/4885KMT2A 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.